SubHero Banner

Tafinlar® (dabrafenib) and Mekinist® (trametinib) – New orphan indication

May 4, 2018 - The FDA announced the approval of Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.

Download PDF